Management of Haemophilia A with Antibodies - The Effect of Combined Treatment with Factor VIII, Hydrocortisone and Cyclophosphamide

Summary

Immune tolerance has by several methods been induced in haemophiliacs with antibodies. A conversion of “high responders” into “low responders” was previously reported after repeated moderate factor IX doses over periods of 7-10 days in combination with cyclophosphamide and steroids in two patients with haemophilia B and inhibitors. This paper reports similar results in a heamophilia A patient by giving factor VIII, cyclophosphamide, and steroids during relatively short periods of time (7-8 days). The anamnestic response markedly decreased already following the first treatment and never exceeded a level of 1 u/ml (˜ 3 BU/ml) even when boosted with ordinary factor VIII doses for only 3 days. It is concluded that the markedly decreased secondary antibody response is most probably the result of factor VIII given at short intervals (twice a day) for periods of up to about one week when given in combination with cyclophosphamide and steroids. The same effect may be achieved by other methods. The treatment schedule suggested in the present paper is, however, simple and avoids long periods of high antibody levels. Furthermore, the total factor VIII dose used is lower than suggested in most other treatment schedules, which makes the treatment substantially less expensive.

Key words

FVIII: C antibodies - FVIII-concentrate - Corticoids - Cyclophosphamide - Haemophilia A - Immunosuppressive therapy - Induced immunotolerance

• References

• 1 Brackmann HH, Gormsen J. Massive factor VIII infusion in a haemophiliac with factor VIII inhibitor, high responder. Lancet 1977; 02: 933
• 2 Brackmann HH, Egli H. Treatment of haemophilia patients with antibodies. In: Seligsohn U. et al. (eds.) Haemophilia Based on Symposia Held during the XHIth Congress of the World Federation of Haemophilia. Tel-Aviv, Israel, 1979. Castle House Publications Ltd; Chichester, Sussex, Great Britain: 1981: 113-119
• 3 White GC, Taylor RE, Blatt PM, Roberts HR. Treatment of a high titer anti-factor VIII antibody by continuous factor VIII administration: Report of a case. Blood 1983; 62: 141-145
• 4 Gomperts ED, Jordan S, Church JA, Sakai R, Lemire J. Induction of tolerance to factor VIII in a child with a high-titer inhibitor: In vitro and in vivo observations. J Pediatr 1984; 104: 70-75
• 5 Hedner U, Nilsson IM. Induced tolerance in haemophilia patients with antibodies against IX:C. Acta Med Scand 1983; 214: 191-197
• 6 Nilsson IM, Sundqvist SB, Ljung R, Holmberg L, Freiburghaus C, Bjorlin G. Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia B and antibodies. Scand J Haematol 1983; 30: 458-464
• 7 Nilsson IM, Kirkwood TB L, Barrowcliffe TW. In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods. Thromb Haemostas 1979; 42: 1230-1239
• 8 Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 1976; 16: 369-382
• 9 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-443
• 10 Frommel D, Gaillander A, Meumer L, Allain JP. Natural history of antibodies to factor VIII. Proceedings of the Xth Congress of the World Federation of Haemophilia. Helsinki 1975: 99 (Abstr).
• 11 Hedner U, Sundqvist SB, Nilsson IM. Immunosuppressive treatment in haemophiliacs with inhibitors. In: Activated Prothrombin Complex Concentrates, Managing Haemophilia with Factor VIII Inhibitor Mariani G. et al. (eds) Praeger, New York, N. Y. 10175, U.S.A.: 1982: 45-54
• 12 Nilsson IM, Hedner U, Bjorlin G. Suppression of factor VIII antibody in haemophilia B by factor IX and cyclophosphamide. Ann Intern Med 1973; 78: 91-95
• 13 Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 1971; 37: 381-387
• 14 Dormandy KM, Sultan Y. The suppression of factor VIII antibodies in haemophilia. Pathol Biol 1975; (Suppl. 23) 17-23
• 15 Hultin MB, Shapiro SS, Bowman HS, Gill FM, Andrews AT, Martinez J, Eyster ME, Sherwood WC. Immunosuppressive therapy of factor VIII inhibitors. Blood 1976; 48: 95-108
• 16 Stenbjerg S, Jørgensen J, Tauris P, Skottum T. Low dose factor VIII for the treatment of haemophilia with inhibitors. In: Activated Prothrombin Complex Concentrates, Managing Haemophilia with Factor VIII Inhibitor Mariani G. et al. (eds). Praeger, New York, N. Y. 10175, U.S.A: 1982: 206-212
• 17 Sultan Y, Maisonneuve P, Sylvestre R. Plasma exchange in the treatment of haemophiliacs with antibodies to factor VIII. In: Activated Prothrombin Complex Concentrates, Managing Haemophilia with Factor VIII Inhibitor Mariani G. et al. (eds). Praeger, New York, N. Y. 10175, U.S.A.: 1982: 55-59
• 18 Rizza CR, Matthews JM. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol 1982; 13: 13-24
• 19 Terman DS, Garcfa-Rinaldi R, Dannemann B, Moore D, Crumb C, Tabel A, Poser R. Specific suppression of antibody rebound after extracorporeal immunoadsorption. I. Comparison of single versus combination-chemotherapeutic agent. Clin Exp Immunol 1978; 34: 32-41
• 20 Kovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: Emphasis on use in rheumatic diseases. Semin Arthritis Rheum 1983; 12: 359-372
• 21 Milligan DW, Delamore IW. Cyclophosphamide in haematological systemic lupus erythematosus. Br Med J 1982; 285: 1352
• 22 Aznar JA, Jorquera JI, Peiro A, Garcia I. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A. Thromb Haemostas 1984; 51: 217-221
• 23 Larsson SA, Nilsson IM, Blombäck M. Current status of Swedish haemophiliacs. I. A demographic survey. Acta Med Scand 1982; 212: 195-200